Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
How Is the Methylmalonic Acidemia (MMA) Market Size Expected to Evolve From 2025 to 2029?
The methylmalonic acidemia (mma) market size has grown strongly in recent years. It will grow from $9.39 billion in 2024 to $9.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to the increasing incidence of metabolic disorders and vitamin deficiencies, increased healthcare expenditure, rise in health consciousness, increasing prevalence of genetic disorders, and growing demand from various end-user industries.
The methylmalonic acidemia (mma) market size is expected to see strong growth in the next few years. It will grow to " $12.4 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing newborn screening programs, increased awareness among healthcare professionals, a rise in gene therapy advancements, rising investments in rare disease research, and increasing availability of specialized treatments. Major trends in the forecast period include advancements in gene editing technologies, advanced diagnostic techniques for early detection, advancements in enzyme replacement therapies, adoption of precision medicine approaches, and adoption of newborn genetic screening programs.
Get your free report sample today:
Which Primary Drivers Are Expected to Shape the Future of the Methylmalonic Acidemia (MMA) Market?
The increasing incidence of metabolic disorders and vitamin deficiencies is expected to propel the growth of the methylmalonic acidemia (MMA) market going forward. Metabolic disorders are a group of conditions in which the body has trouble processing certain nutrients, producing energy, or regulating chemical reactions within cells. Vitamin deficiencies occur when the body lacks enough specific vitamins to perform normal functions. The rise in metabolic disorders and vitamin deficiencies is due to unhealthy diets, sedentary lifestyles, and increased stress levels. Modern diets are often high in processed foods, sugars, and unhealthy fats while low in essential nutrients, leading to deficiencies in vitamins and minerals. Metabolic disorders and vitamin deficiencies, particularly vitamin B12 deficiency, impair methylmalonyl-CoA metabolism, accumulating methylmalonic acid and exacerbating methylmalonic acidemia (MMA). For instance, in November 2024, according to the National Institutes of Health, a US-based government agency, the prevalence of vitamin B12 deficiency increased from 4.6% to 5.2%, representing an additional 507 cases between the third and fourth quarters of 2023. Therefore, the increasing incidence of metabolic disorders and vitamin deficiencies drives the growth of the methylmalonic acidemia (MMA) market.
How Is the Methylmalonic Acidemia (MMA) Market Categorized Based on Key Segments?
The methylmalonic acidemia (mma)market covered in this report is segmented –
1) By Indication: Acidosis; Ketosis; Hyperammonemia; Hypoglycaemia; Hyperglycaemia; Neutropenia; Other Indications
2) By Disorder Type: Homocystinuria; Isolated Methylmalonic Acidurias; Combined methylmalonic Aciduria
3) By Distribution Channel: Hospitals; Pharmacies; Clinics; Other Distribution Channels
Subsegments:
1) By Acidosis: Metabolic Acidosis; Lactic Acidosis
2) By Ketosis: Starvation-Induced Ketosis; Diabetic Ketoacidosis
3) By Hyperammonemia: Acute Hyperammonemia; Chronic Hyperammonemia
4) By Hypoglycemia: Fasting Hypoglycemia; Reactive Hypoglycemi
5) By Hyperglycemia: Transient Hyperglycemia; Persistent Hyperglycemia
6) By Neutropenia: Severe Neutropenia; Cyclic Neutropenia
7) By Other Indications: Failure to Thrive; Developmental Delays; Neurological Symptoms; Renal Dysfunction
What Are the Key Industry Trends Driving Growth in the Methylmalonic Acidemia (MMA) Market?
Major companies operating in the methylmalonic acidemia (MMA) market are focusing on developing innovative solutions, such as mRNA-based therapies, to improve treatment outcomes by targeting the underlying genetic causes of MMA and enhancing enzyme function to reduce the accumulation of toxic metabolites in affected individuals. mRNA-based therapies are a type of treatment that uses messenger RNA to instruct cells to produce specific proteins that can help prevent or treat diseases, such as genetic disorders or infections. For instance, In June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, received U.S. Food and Drug Administration (FDA) approval for including mRNA-3705 in the START pilot program, marking a significant step in advancing treatments for rare diseases. mRNA-3705 is an investigational therapy for methylmalonic acidemia (MMA) caused by MUT deficiency, designed to restore the missing enzyme using mRNA technology. The therapy leverages Moderna's proprietary lipid nanoparticle (LNP) system, also utilized in the mRNA-3927 program for propionic acidemia. The FDA has granted mRNA-3705 orphan drugs, fast track, and rare pediatric disease designations, facilitating its accelerated development and clinical progress.
Who Are the Established and Emerging Companies Competing in the Methylmalonic Acidemia (MMA) Market?
Major companies operating in the methylmalonic acidemia (MMA) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.
Get the detailed methylmalonic acidemia (mma) market report today
Which Region Is Expected to Dominate the Methylmalonic Acidemia (MMA) Market During the Forecast Period?
North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (MMA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment